Business description
Werewolf Therapeutics is a highly innovative company striving to redefine the cancer treatment landscape with potential best-in-class therapies. It develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. They invented proprietary PREDATOR™ protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients.
Management board & Supervisory board
| CEO |
| Dan Hicklin |
| Management board |
| Tim Trost, Randi Isaacs, Chulani Karunatilake, Ellen Lubman, Cynthia Seidel-Dugan |
| Supervisory board |
| Luke Evnin, Michael Atkins, Meeta Chatterjee, Derek DiRocco, Dan Hicklin, Alon Lazarus, Briggs W. Morrison, Mike Sherman |
Company data
| Name: |
Werewolf Therapeutics Inc |
| Address: |
200 Talcott Avenue, 2nd Floor,Watertown, MA 02472 |
| Phone: |
+1 617-952-0555 |
| Fax: |
- |
| E-mail: |
info@werewolftx.com
|
| Internet: |
https://werewolftx.com/ |
| Industry: |
Biotechnology |
| Sector: |
Biotechnology |
| Sub sector: |
- |
| End of financial year: |
12/31 |
| Free Float: |
- |
| IPO date: |
4/29/2021 |
Investor relations
| Name: |
Josh Rappaport |
| IR phone: |
+1 212-362-1200 |
| IR Fax: |
- |
| IR e-mail: |
IR@werewolftx.com
|
